MedTrace Logo

Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients

NCT01648205 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-04-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether late sodium channel blockade might be effective in shortening the QTc interval in various LQT3 mutations and be considered as a safe therapeutic option for LQT3 patients.

Conditions

  • Long QT Syndrome

Interventions

DRUG

Placebo

Matching Placebo will be given for first month.

DRUG

Ranolazine

Patients will receive ranolazine 1000mg bid for subsequent 5 months.

Sponsors & Collaborators

Principal Investigators

  • Wojciech Zareba, MD,PhD · University of Rochester

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2018-07-20
Completion
2018-07-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01648205 on ClinicalTrials.gov